Although there are a number of vaccines available for influenza it is widely recognised there is a desperate need for new ones, see WHO report here https://www.who.int/immunization/research/meetings_workshops/Universal_Influenza_VaccineRD_Sept2014.pdf and CDC site here https://www.cdc.gov/flu/
And in particular better vaccines are needed for more vulnerable groups, see link here https://www.cdc.gov/flu/about/disease/high_risk.htm
There is now increasing interest and growing evidence to support respiratory routes of vaccination. For example, ongoing Phase 1 clinical trials are looking at the efficacy of the Oxford/Astra-Zeneca SARS-CoV-2 vaccine when delivered via the inhalational route. However, our technology has the advantage of low-dose vaccination which is inherently more boostable, more cost-effective, quicker to manufacture therefore more suitable for the logistical challenges of the developing world and less likely to induce unwanted side-effects.
Our approach provides cross protection against related strains and potentially many advantages over other vaccines in development, see WHO link above.